Search research articles
Contact Us
Filters
Showing results (311-320 of 678) with videos related to
Page
of 68
Sort By:
Neurology
|
July 1, 1994
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors
A Antonini, J Schwarz, W H Oertel, et al.
Veterinary Parasitology
|
July 13, 2000
Effects of Psoroptes ovis infection and its control with an ivermectin controlled-release capsule on growing sheep. 2. Evaluation of wool production and leather value
S Rehbein, H Oertel, D Barth, et al.
Life Sciences
|
January 1, 1983
Opioid peptide-like immunoreactivity localized in GABAErgic neurons of rat neostriatum and central amygdaloid nucleus
W H Oertel, G Riethmüller, E Mugnaini, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 24, 2006
Modulation of human motor cortex excitability by single doses of amantadine
Janine Reis, Daniel John, Antje Heimeroth, et al.
Headache
|
September 12, 2008
Serum concentrations of s100b and NSE in migraine
Michael Teepker, Karoline Munk, Veit Mylius, et al.
European Journal of Neurology
|
August 22, 2008
Clinical risk-benefit assessment of dopamine agonists
J C Möller, K M Eggert, M Unger, et al.
Experimental Neurology
|
August 18, 2009
Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies
Matthias Höllerhage, Andreas Matusch, Pierre Champy, et al.
Neuroscience Letters
|
November 6, 2012
Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease
Candan Depboylu, Matthias Höllerhage, Stefan Schnurrbusch, et al.
Der Nervenarzt
|
January 9, 2014
[REM sleep behavior disorder as a prodromal stage of α-synucleinopathies: symptoms, epidemiology, pathophysiology, diagnosis and therapy]
W H Oertel, C Depboylu, M Krenzer, et al.
Pharmacoeconomics
|
August 5, 1998
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis
R C Dodel, M Singer, R Köhne-Volland, et al.
Page
of 68
Search research articles
Search
Showing results (311-320 of 678) with videos related to
Sort By:
Page
of 68
Neurology
|
July 1, 1994
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors
A Antonini, J Schwarz, W H Oertel, et al.
Veterinary Parasitology
|
July 13, 2000
Effects of Psoroptes ovis infection and its control with an ivermectin controlled-release capsule on growing sheep. 2. Evaluation of wool production and leather value
S Rehbein, H Oertel, D Barth, et al.
Life Sciences
|
January 1, 1983
Opioid peptide-like immunoreactivity localized in GABAErgic neurons of rat neostriatum and central amygdaloid nucleus
W H Oertel, G Riethmüller, E Mugnaini, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 24, 2006
Modulation of human motor cortex excitability by single doses of amantadine
Janine Reis, Daniel John, Antje Heimeroth, et al.
Headache
|
September 12, 2008
Serum concentrations of s100b and NSE in migraine
Michael Teepker, Karoline Munk, Veit Mylius, et al.
European Journal of Neurology
|
August 22, 2008
Clinical risk-benefit assessment of dopamine agonists
J C Möller, K M Eggert, M Unger, et al.
Experimental Neurology
|
August 18, 2009
Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies
Matthias Höllerhage, Andreas Matusch, Pierre Champy, et al.
Neuroscience Letters
|
November 6, 2012
Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease
Candan Depboylu, Matthias Höllerhage, Stefan Schnurrbusch, et al.
Der Nervenarzt
|
January 9, 2014
[REM sleep behavior disorder as a prodromal stage of α-synucleinopathies: symptoms, epidemiology, pathophysiology, diagnosis and therapy]
W H Oertel, C Depboylu, M Krenzer, et al.
Pharmacoeconomics
|
August 5, 1998
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis
R C Dodel, M Singer, R Köhne-Volland, et al.
Page
of 68